CTMX CytomX Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTMX

Price (delayed)

$4.43

Market cap

$300.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.01

Enterprise value

$295.89M

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics, ...

Highlights
CytomX Therapeutics's net income has surged by 99% YoY and by 94% QoQ
The EPS has soared by 99% YoY and by 94% from the previous quarter
CTMX's debt is up by 32% since the previous quarter but it is down by 23% year-on-year
CTMX's quick ratio is down by 24% year-on-year and by 15% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cytomx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CTMX
Market
Shares outstanding
67.72M
Market cap
$300.01M
Enterprise value
$295.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.23
EV/EBIT
89.04
EV/EBITDA
32.07
EV/Sales
2.92
Earnings
Revenue
$101.21M
EBIT
$3.32M
EBITDA
$9.23M
Free cash flow
-$56.88M
Per share
EPS
-$0.01
Free cash flow per share
-$0.77
Book value per share
-$0.71
Revenue per share
$1.37
TBVPS
$2.71
Balance sheet
Total assets
$201.79M
Total liabilities
$249.24M
Debt
$13.97M
Equity
-$47.45M
Working capital
$27.02M
Liquidity
Debt to equity
-0.29
Current ratio
1.17
Quick ratio
1.15
Net debt/EBITDA
-0.45
Margins
EBITDA margin
9.1%
Gross margin
100%
Net margin
-0.6%
Operating margin
-6.4%
Efficiency
Return on assets
-0.3%
Return on equity
N/A
Return on invested capital
8.7%
Return on capital employed
7.2%
Return on sales
3.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTMX stock price

How has the CytomX Therapeutics stock price performed over time
Intraday
-1.56%
1 week
178.62%
1 month
106.05%
1 year
168.48%
YTD
185.81%
QTD
103.21%

Financial performance

How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$101.21M
Gross profit
$101.21M
Operating income
-$6.48M
Net income
-$569,000
Gross margin
100%
Net margin
-0.6%
CTMX's net margin has surged by 100% year-on-year and by 94% since the previous quarter
CytomX Therapeutics's net income has surged by 99% YoY and by 94% QoQ
The company's operating margin has surged by 97% YoY and by 60% QoQ
The operating income has soared by 94% year-on-year and by 58% since the previous quarter

Growth

What is CytomX Therapeutics's growth rate over time

Valuation

What is CytomX Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.23
EV/EBIT
89.04
EV/EBITDA
32.07
EV/Sales
2.92
The EPS has soared by 99% YoY and by 94% from the previous quarter
CTMX's equity is up by 45% year-on-year and by 7% since the previous quarter
The stock's P/S is 148% more than its last 4 quarters average of 1.3 but 47% less than its 5-year quarterly average of 6.1
CTMX's revenue has surged by 90% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is CytomX Therapeutics business performance
The ROS has soared by 142% from the previous quarter and by 102% YoY
The ROIC has soared by 113% QoQ and by 101% YoY
CTMX's return on assets has surged by 99% year-on-year and by 93% since the previous quarter

Dividends

What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTMX.

Financial health

How did CytomX Therapeutics financials performed over time
CTMX's total assets is 19% less than its total liabilities
The company's total liabilities fell by 28% YoY and by 9% QoQ
The company's current ratio fell by 25% YoY and by 15% QoQ
CTMX's debt is 129% greater than its equity
CTMX's equity is up by 45% year-on-year and by 7% since the previous quarter
The debt to equity has declined by 38% since the previous quarter and by 38% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.